CEL-SCI Sees Unusually High Options Volume (NYSEAMERICAN:CVM)

CEL-SCI Co. (NYSEAMERICAN:CVM) was the recipient of some unusual options trading on Monday. Investors bought 13,058 call options on the stock. This represents an increase of 1,088% compared to the typical daily volume of 1,099 call options.

In related news, CEO Geert R. Kersten purchased 6,631 shares of CEL-SCI stock in a transaction that occurred on Friday, January 10th. The shares were acquired at an average cost of $7.78 per share, for a total transaction of $51,589.18. Following the transaction, the chief executive officer now directly owns 1,114,538 shares in the company, valued at $8,671,105.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CVM. Wells Fargo & Company MN lifted its holdings in CEL-SCI by 1,924.1% in the 2nd quarter. Wells Fargo & Company MN now owns 28,965 shares of the company’s stock worth $243,000 after buying an additional 27,534 shares during the period. JPMorgan Chase & Co. purchased a new position in CEL-SCI during the second quarter valued at $57,000. Charles Schwab Investment Management Inc. raised its stake in CEL-SCI by 350.5% during the second quarter. Charles Schwab Investment Management Inc. now owns 70,516 shares of the company’s stock valued at $591,000 after buying an additional 54,863 shares during the last quarter. Bank of New York Mellon Corp raised its stake in CEL-SCI by 109.2% during the second quarter. Bank of New York Mellon Corp now owns 74,916 shares of the company’s stock valued at $628,000 after buying an additional 39,098 shares during the last quarter. Finally, Northern Trust Corp raised its stake in CEL-SCI by 104.1% during the second quarter. Northern Trust Corp now owns 78,243 shares of the company’s stock valued at $656,000 after buying an additional 39,915 shares during the last quarter.

Separately, HC Wainwright initiated coverage on CEL-SCI in a research report on Monday. They set a “buy” rating and a $18.00 price target on the stock.

CVM traded up $0.12 on Tuesday, hitting $9.46. 46,337 shares of the company were exchanged, compared to its average volume of 980,787. CEL-SCI has a 12 month low of $2.37 and a 12 month high of $9.99.

CEL-SCI (NYSEAMERICAN:CVM) last posted its quarterly earnings results on Monday, December 16th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.11). The company had revenue of $0.08 million during the quarter, compared to analyst estimates of $0.10 million.

About CEL-SCI

CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and other diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of primary head and neck cancer. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer.

Read More: What is a dividend reinvestment plan?

Receive News & Ratings for CEL-SCI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CEL-SCI and related companies with MarketBeat.com's FREE daily email newsletter.